Omigapil (TCH346 or CGP3466) is a drug that was developed by Novartis and tested in clinical trials for its ability to help treat Parkinson's disease (PD)...

degeneration. Agents currently under investigation include antiapoptotics (omigapil, CEP-1347), antiglutamatergics, monoamine oxidase inhibitors (selegiline...

selegiline, vitamin E, and coenzyme Q); anti-apoptotic drugs (pentoxyfilline, omigapil, and minocycline); and drugs to improve mitochondria function (creatine...

investigation as neuroprotective agents include anti-apoptotic drugs (omigapil, CEP-1347), antiglutamatergic agents, monoamine oxidase inhibitors (selegiline...